Please try another search
As of August 21, 2018, Medical Prognosis Institute A/S was acquired by Oncology Venture Sweden AB, in a reverse merger transaction. Medical Prognosis Institute A/S, a precision medicine company, develops medicines to treat cancer using its Drug Response Predictor (DRP) technology. The company uses its DRP, a tool for developing tumor-derived genetic signatures to predict which cancer patients are high likely to respond to a given anti-cancer product. The company’s product consist of LiPlaCis, which is in Phase I/II studies to treat patient with metastatic breast cancer; and APO010, an immuno-oncology drug, which is in Phase I/II studies for multiple myeloma. Medical Prognosis Institute A/S was founded in 2004 and is headquartered in Hørsholm, Denmark.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review